Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
How this insider trader nailed every single stock trade
04:54am, Friday, 05'th Apr 2024
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
10:33am, Thursday, 11'th Jan 2024
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC)
Cramer names biopharma companies to watch as industry mergers start to pile up
07:02pm, Friday, 05'th Jan 2024
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
12:47pm, Wednesday, 06'th Dec 2023
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
Mirati's lung cancer drug gets EU's regulatory backing
09:02am, Friday, 10'th Nov 2023
Mirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer.
SAN DIEGO, Calif. and ZUG, Switzerland , Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examin
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Thera
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
09:01am, Tuesday, 07'th Nov 2023
Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
08:00am, Monday, 06'th Nov 2023
SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with
SAN DIEGO and ZUG, Switzerland , Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and He
Bristol-Myers Squibb Acquisition Of Mirati Makes Sense
08:53am, Sunday, 22'nd Oct 2023
Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati Therapeutics, including its oncology drug Krazati,
SAN DIEGO , Oct. 17, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2 study eval
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
12:47pm, Tuesday, 10'th Oct 2023
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
05:16pm, Monday, 09'th Oct 2023
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion
